Cargando…

Statin use and hip fractures in U.S. kidney transplant recipients

BACKGROUND: Basic and translational research supports beneficial effects of statins on bone metabolism. Clinical studies suggest that statin use may reduce the risk of hip fractures in the general population. Whether statin use is associated with hip fracture risk in kidney transplant recipients, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vangala, Chandan, Lenihan, Colin R., Montez-Rath, Maria E., Nair, Sumi Sukumaran, Navaneethan, Sankar D., Ramanathan, Venkat, Winkelmayer, Wolfgang C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412039/
https://www.ncbi.nlm.nih.gov/pubmed/28460645
http://dx.doi.org/10.1186/s12882-017-0559-9
_version_ 1783232907631919104
author Vangala, Chandan
Lenihan, Colin R.
Montez-Rath, Maria E.
Nair, Sumi Sukumaran
Navaneethan, Sankar D.
Ramanathan, Venkat
Winkelmayer, Wolfgang C.
author_facet Vangala, Chandan
Lenihan, Colin R.
Montez-Rath, Maria E.
Nair, Sumi Sukumaran
Navaneethan, Sankar D.
Ramanathan, Venkat
Winkelmayer, Wolfgang C.
author_sort Vangala, Chandan
collection PubMed
description BACKGROUND: Basic and translational research supports beneficial effects of statins on bone metabolism. Clinical studies suggest that statin use may reduce the risk of hip fractures in the general population. Whether statin use is associated with hip fracture risk in kidney transplant recipients, a particularly high-risk group for this outcome, is unknown. METHODS: From the U.S. Renal Data System (2007–2011), we identified all hip fracture events recorded in Medicare billing claims of first-time kidney transplant recipients. We then matched all cases to an unlimited number of controls on age (±3 years), sex, race (black vs. non-black), and time since transplant. Cases and controls were required to have >1 year of Medicare Parts A + B + D coverage and be without a recorded history of hip fracture. We ascertained any statin use in the previous year and defined adherent statin use as those who had filled prescriptions for statins to cover >80% of days in that year (proportion of days covered, PDC). We ascertained several potential confounders (demographics, comorbidities, BMI, transplant-related factors) and applied conditional logistic regression with multiple imputation for missing data to estimate odds ratios (OR) and 95% confidence intervals (CI). RESULTS: We identified 231 hip fracture cases (mean age 51.8 years; 53% female; 11.3% black; 6.9 years from transplant, and 9.9 years from ESRD) and 15,575 matched controls. Any prior statin use was present in 64.1% of cases and 60.3% of controls with 37.2% of cases and 33.9% of controls being found adherent. Unadjusted conditional logistic regression showed an OR of 1.17 (0.89-1.54) for any statin use, and a fully-adjusted OR of 0.89 (0.67-1.19). Compared with statin non-users, the adjusted OR for patients with lesser adherence (PDC ≤80%) and those with greater adherence (PDC >80%) were 0.93 (0.66-1.31) and 0.87 (0.63-1.20), respectively. CONCLUSION: Statin use was not associated with hip fracture risk in first-time kidney transplant recipients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0559-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5412039
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54120392017-05-03 Statin use and hip fractures in U.S. kidney transplant recipients Vangala, Chandan Lenihan, Colin R. Montez-Rath, Maria E. Nair, Sumi Sukumaran Navaneethan, Sankar D. Ramanathan, Venkat Winkelmayer, Wolfgang C. BMC Nephrol Research Article BACKGROUND: Basic and translational research supports beneficial effects of statins on bone metabolism. Clinical studies suggest that statin use may reduce the risk of hip fractures in the general population. Whether statin use is associated with hip fracture risk in kidney transplant recipients, a particularly high-risk group for this outcome, is unknown. METHODS: From the U.S. Renal Data System (2007–2011), we identified all hip fracture events recorded in Medicare billing claims of first-time kidney transplant recipients. We then matched all cases to an unlimited number of controls on age (±3 years), sex, race (black vs. non-black), and time since transplant. Cases and controls were required to have >1 year of Medicare Parts A + B + D coverage and be without a recorded history of hip fracture. We ascertained any statin use in the previous year and defined adherent statin use as those who had filled prescriptions for statins to cover >80% of days in that year (proportion of days covered, PDC). We ascertained several potential confounders (demographics, comorbidities, BMI, transplant-related factors) and applied conditional logistic regression with multiple imputation for missing data to estimate odds ratios (OR) and 95% confidence intervals (CI). RESULTS: We identified 231 hip fracture cases (mean age 51.8 years; 53% female; 11.3% black; 6.9 years from transplant, and 9.9 years from ESRD) and 15,575 matched controls. Any prior statin use was present in 64.1% of cases and 60.3% of controls with 37.2% of cases and 33.9% of controls being found adherent. Unadjusted conditional logistic regression showed an OR of 1.17 (0.89-1.54) for any statin use, and a fully-adjusted OR of 0.89 (0.67-1.19). Compared with statin non-users, the adjusted OR for patients with lesser adherence (PDC ≤80%) and those with greater adherence (PDC >80%) were 0.93 (0.66-1.31) and 0.87 (0.63-1.20), respectively. CONCLUSION: Statin use was not associated with hip fracture risk in first-time kidney transplant recipients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0559-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-01 /pmc/articles/PMC5412039/ /pubmed/28460645 http://dx.doi.org/10.1186/s12882-017-0559-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Vangala, Chandan
Lenihan, Colin R.
Montez-Rath, Maria E.
Nair, Sumi Sukumaran
Navaneethan, Sankar D.
Ramanathan, Venkat
Winkelmayer, Wolfgang C.
Statin use and hip fractures in U.S. kidney transplant recipients
title Statin use and hip fractures in U.S. kidney transplant recipients
title_full Statin use and hip fractures in U.S. kidney transplant recipients
title_fullStr Statin use and hip fractures in U.S. kidney transplant recipients
title_full_unstemmed Statin use and hip fractures in U.S. kidney transplant recipients
title_short Statin use and hip fractures in U.S. kidney transplant recipients
title_sort statin use and hip fractures in u.s. kidney transplant recipients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412039/
https://www.ncbi.nlm.nih.gov/pubmed/28460645
http://dx.doi.org/10.1186/s12882-017-0559-9
work_keys_str_mv AT vangalachandan statinuseandhipfracturesinuskidneytransplantrecipients
AT lenihancolinr statinuseandhipfracturesinuskidneytransplantrecipients
AT montezrathmariae statinuseandhipfracturesinuskidneytransplantrecipients
AT nairsumisukumaran statinuseandhipfracturesinuskidneytransplantrecipients
AT navaneethansankard statinuseandhipfracturesinuskidneytransplantrecipients
AT ramanathanvenkat statinuseandhipfracturesinuskidneytransplantrecipients
AT winkelmayerwolfgangc statinuseandhipfracturesinuskidneytransplantrecipients